The Control Gap: Who's In the Room?
- Jonathan Olsen
- 2 days ago
- 2 min read
The pharma launch market has settled the question of which tools to use. It still hasn't answered the only question that decides the launch: who is in the room.
The short version:
The platforms are real and the value is there, but the edge was never in owning the software.
The gap nobody sells into is the person who runs it against your molecule, with authority to act.
The 2027 launches that look effortless will belong to whoever put control back in the room.
Six posts ago I made a single claim, that structure isn't control, and this is where it lands. Every major firm is now selling a platform or a seat, whether that's an agentic suite, a next-best-action engine, a success predictor, or MLR automation, and all of it is powerful, real, and increasingly table stakes. McKinsey sizes the commercial-AI prize at 18 to 30 billion dollars, Deloitte models up to 7 billion for a single large biopharma, and the value is there.
But the value was never in owning the platform. EVERSANA's Faruk Capan has said it plainly, arguing that the AI platforms most at risk are the closed, black-box ones, and that leaders shouldn't hand their entire AI strategy to whoever happens to own the tool. The edge isn't the software, it's owning how the software gets run.
A platform doesn't run a launch. A team does.
And the gap nobody is selling into is the one between the tool and the asset. It's the person who orchestrates these systems against your molecule, your market, and your access reality, the person in the room with the authority to turn a week-three signal into a Friday decision, and the person who stays accountable for keeping the loop closed when the market moves. When Pfizer's Charlie shows up as a real launch advantage, it isn't because the software is magic, it's because someone built it around their assets and runs it against their launches, and that part you cannot buy off a shelf.
One last thing, because it's easy to lose in the language of platforms and loops. A launch that drifts is not just a missed number. Somewhere behind it is a patient waiting longer for a therapy that already exists, and that is the reason the execution deserves this much care.
The companies whose 2027 launches look effortless won't be the ones that bought the most AI. They'll be the ones that put control back in the room.
If you're launching in the next 18 months, what changes the moment one person owns the loop end to end?
That embedded-operator role is exactly what we do at Ivy Tree, running the modern launch stack from inside your team and against your asset. If a launch is on your horizon and this has been on your mind, let's talk. DM me or leave a comment.
Comments